MSLN and melanoma: The association between anti-programmed cell death 1 (PD-1) therapy and activation of CD8 T cells specific for mutated antigens in melanoma [26, 27] may warrantstudies with mutated mesothelin-specific responses in patients with GBM undergoing immune checkpoint blockade therapy [28].